Manager TitleAgeSince
Chief Executive Officer 72 -
General Counsel - -
Sales & Marketing - 2014-09-09
Director TitleAgeSince
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.26%+0.13%+36.74%+5.60% 12.54B
+0.52%-0.95%+14.24%+19.11% 6.47B
-0.53%-5.32%+40.76%+18.75% 5.48B
+3.06%-0.59% - - 4.73B
-3.39%+1.63%-27.68%+19.43% 4.32B
-2.85%-2.49%-25.86%-23.96% 3.92B
-11.71%+10.87%+46.59%-54.71% 2.06B
-0.34%-4.23%-11.45%+197.57% 1.72B
+0.33%+0.33%+55.09%-5.26% 1.55B
Average -1.63%-1.08%+16.05%+22.07% 4.75B
Weighted average by Cap. -0.74%-1.46%+18.83%+13.28%
Logo ArtVentive Medical Group Inc
ArtVentive Medical Group, Inc. is a medical device company. The Company is focused on developing, manufacturing and marketing a family of endoluminal occlusion devices, known as the ArtVentive Endoluminal Occlusion System (ArtVentive EOS or EOS). Through its technology, it has developed minimally invasive occlusion devices and procedures capable of achieving occlusion of peripheral vasculature. EOS serves as a technology platform for various clinical areas, including peripheral and neurological vascular disorders, women's health, interventional oncology and cardiology procedures. EOS is designed to be deployed into an artery, vein or tube using the Company's catheter and placed in the correct place to cut off blood or fluid supply. The EOS delivery catheter is designed to permit controlled deployment, with instantaneous occlusion of the treated vessel. It focuses on developing Catheter-Assisted Endovascular Tumor Treatment (CAETT) system.
Employees
-